The frequency of cytogenetic abnormalities in the Philadelphianegative myeloproliferative neoplasms (MPNs) varies from approximately 30% in primary myelofibrosis (PMF) to less than 5% in essential thrombocytosis (ET). The spectrum of aberrations is heterogeneous, ranging from gains and losses of genetic material to structural changes including unbalanced translocations. However, no specific abnormality has been identified to date. Nevertheless, such investigations can provide evidence of clonality and, as a result, cytogenetic findings have been included in the WHO diagnostic criteria for this group of diseases. The aim of the current review is to discuss the pathogenetic insight and prognostic information that standard, as well as molecular cytogenetic analysis has provided. A brief overview is given of the cytogenetic findings in the individual diseases, followed by a more detailed discussion of the possible pathogenetic consequences of specific abnormalities and their impact on prognosis.
Introduction
The myeloproliferative neoplasms (MPNs), as defined by the recent WHO classification, 1 represent a spectrum of clonal conditions in which acquired mutations result in disordered haematopoiesis. Standard cytogenetic analysis has been a pivotal step in the elucidation of pathogenetically relevant oncogenes in many haematological malignancies, the paradigm being the identification of the Philadelphia chromosome in chronic myeloid leukaemia. 2 This discovery led to the elucidation of the critical pathogenetic role of the BCR-ABL fusion gene 3, 4 and to the development of successful targeted therapy. 5 Subsequently, other oncogenic events, involving fusion genes encoding different tyrosine kinases, have been identified by studying rare translocations, including those involving PDGFR-b gene, 6,7 FLIP1L1-PDGFRa 8 as well as a number of chimeric genes resulting from the rearrangement of the FGFR1 gene (see review Bain BJ 9 ). In contrast, despite the publication of many cytogenetic studies, the pathogenesis of the Philadelphianegative myeloproliferative neoplasms namely, polycythaemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has, until recently, defied molecular explanation. In 2005, however, five research groups that used the approach of studying tyrosine kinases, reported an identical 'gain-offunction' mutation in the cytoplasmic tyrosine kinase JAK2 that is not detectable by cytogenetic analysis. [10] [11] [12] [13] [14] Karyotypic analysis, however, still has a place in the routine evaluation of patients with MPNs, as an abnormal cytogenetic profile provides evidence of clonality, a factor that has been retained in the proposed revision of WHO diagnostic criteria for the BCR-ABL-negative MPDs. 15 In addition, the authors of a recent, critical review of the WHO proposals, supported the diagnostic importance of cytogenetic analysis for PMF, as well as for cases of ET that have an associated anaemia, macrocytosis, leucopenia and/or extramedullary haematopoiesis. 16 The aim of this review is to discuss the pathogenetic insight and prognostic information that standard, as well as molecular cytogenetic analysis has provided. A brief overview is given (for summary see Table 1 ), followed by a more detailed discussion of the possible pathogenetic consequences of specific abnormalities and their impact on prognosis.
Overview

Primary myelofibrosis
Cytogenetic analysis has provided support for the current pathogenetic model of PMF, in which cytokine release from clonal haematopoiesis is thought to stimulate a polyclonal, or reactive stromal proliferation. 17 Karyotypic analysis, for example, has confirmed the clonal involvement of erythroid, granulocyte-monocyte and granulocyte-monocyte-erythroid progenitors, in contrast to bone marrow fibroblasts which appear to be cytogenetically normal. 18, 19 Similar conclusions were reached in an earlier study of chronic myeloid leukaemia. 20 Cytogenetic evaluation is recommended in all cases of PMF, not just to confirm clonality but also to exclude rare cases of chronic myeloid leukaemia (CML) presenting with a similar phenotype. 21, 22 PMF has the highest aberration rate of the Philadelphianegative MPNs, with a third having an abnormal karyotype at diagnosis. 23, 24 It has been suggested, however, that many of these changes may represent secondary subclones resultant upon the genetic instability of the original clone. 25 Over the last 15 years the publication of three large studies, involving a total of 256 well characterized patients, has helped to clarify the cytogenetic profile of PMF cases. [26] [27] [28] These studies, as well as a literature review of 157 abnormal cases 29 has revealed that deletions of 13q and 20q, trisomy 8 and abnormalities of chromosomes 1, 7 and 9 constitute more than 80% of all chromosomal changes. Deletions of 13q are the most common karyotypic abnormality, occurring in approximately 25% of cases with an abnormal cytogenetic analysis. 26, 27, 30 The second and third most common abnormalities are deletions of 20q and partial duplication of the long arm of chromosome 1 respectively. 26, 27 These three lesions, however, are not specific for PMF and have also been reported in polycythaemia vera, myelodysplastic syndrome and other haematological malignancies. In contrast, the abnormality der(6)t(1;6)(q23-25;p21-22) has been recently identified as a possible marker for PMF, although it is scarce occurring in less than 3% of cases. 31 Interestingly, the involved region (6p21) contains the FK-506-binding protein 5 (FKBP51) gene which has been shown to be overexpressed in CD34 þ cell-derived megakaryocytes from PMF patients. It has been suggested that this protein may confer an anti-apoptotic effect through inhibition of calcineurin. 32 Finally, a patient with PMF and t(5;12)(q22;q13), associated with a novel TEL-PDGFRb fusion transcript, has been reported that responded to imatinib therapy. This case suggests that tyrosine kinase activations other than JAK2 and MPL mutations may also be responsible for the pathogenesis of rare cases of PMF. 33 Recent studies, using oligonucleotide microarrays on purified CD34 þ cells, have highlighted a complexity in PMF far greater than suggested by standard cytogenetics. For example, Jones et al. 34 have identified 95 highly differentially expressed genes, of which 75 could be used to accurately differentiate PMF CD34 þ cells from control cells by hierarchical clustering. Furthermore, Guglielmelli et al. 35 noted 174 differentially expressed genes and found that a set of only eight of these genes could separate, not only PMF CD34 cells from controls, but also PMF granulocytes from those of PV and ET. Finally, loss of heterozygosity (LOH) studies have highlighted RARb2 to be a candidate tumour suppressor gene in PMF, although for most patients, epigenetic changes, rather than gene deletion, may be the most significant determinant of reduced activity. 36 
Essential thrombocythaemia
Cytogenetic abnormalities in ET are uncommon and occur in less than 5% of cases. [37] [38] [39] No consistent abnormality characterizes the disease, as many of the common clonal changes, including trisomies 8 and 9 and deletions in 13q and 20q, are also observed in PV and PMF. 29, 40 Interphase FISH studies have been used in an attempt to clarify the frequency of such abnormalities in ET. Zamora et al. 41 for example, reported a higher detection rate (15%) using FISH probes for the four defects listed above, when compared with standard cytogenetics. Similar findings have been reported for trisomies 8 and 9 by some groups 42 but not by others. 43 A number of reasons have been proposed for these discrepant findings, including the different length of patient follow up, the concomitant use of cytoreductive therapy, as well as the source material analysed. 41 However, data from the Mayo Clinic suggests that results from peripheral blood may be comparable to those obtained from bone marrow. 44, 45 Interestingly, Steensma and Tefferi, 46 in a review of the literature, have emphasized that abnormalities of nearly every chromosome have been reported in individual patients, a finding that might indicate a bystander effect, at least in some cases. Karyotypic abnormalities, however, are more common following leukaemic transformation, as is the case for all the MPNs, with frequencies of around 90%, 26, 37, 46 a finding consistent with the multistep process of leukaemogenesis. The majority of leukaemic transformations in MPNs exhibit 'high risk' cytogenetic changes, including À5/5qÀ and À7/À7q and, as a result, respond dismally to chemotherapy. 47 Finally, it has been proposed that cytogenetic analysis should be undertaken in all cases of ET, as rarely CML may present with an identical phenotype. [48] [49] [50] Although such presentations are rare, the success of tyrosine kinase inhibitors in CML makes it important that such a diagnosis is not missed. 51 Finally, cytogenetic analysis of haematopoietic colonies suggests that, at least in some patients, the disease can arise at the multipotent stem cell level. 52 
Polycythaemia vera
The incidence of cytogenetic abnormalities has been reported in a limited number of patients, both at diagnosis and during different stages of the disease, including treated and untreated patients. [53] [54] [55] [56] Although no specific abnormality has been reported to date, less than 20% of patients have chromosomal abnormalities in the bone marrow at the time of diagnosis 54, 55, 58 and the use of interphase FISH does not appear to significantly increase the detection rate in untreated patients. 59 The common changes at presentation are trisomies for 1q, 8, 9, as well as del (20) (q11) , 53, 54 although many different changes have been associated with PV. 54, 57, 58, 60 Furthermore, 13q-and chromosome 1 abnormalities have been correlated with disease transformation to myelofibrosis. 53, 54 The only parameter Critical region (p13-pter) [87] [88] [89] Involvement JAK2 V617F associated with an abnormal karyotype appears to be age, in contrast to JAK2V617F allele burden, thrombosis, haemorrhage, leukaemic/fibrotic transformation or survival. 58 Interestingly, specific therapies are associated with a much higher frequency of abnormalities. For example, in the study of 104 cases by Diez-Martin et al., 54 13% of patients who had not received treatment possessed a chromosomal abnormality, compared with 56% of patients who had received radioactive phosphorous, or cytotoxic agents, particularly busulphan. A further study demonstrated abnormalities in 18% treated with phlebotomy alone, which increased to 60% in those receiving myelosuppressive agents.
Chronic neutrophilic leukaemia
Chronic neutrophilic leukaemia (CNL) is a rare, but distinct MPN, characterized by a sustained mature neutrophilia in peripheral blood, hepatosplenomegaly, lack of detectable BCR-ABL transcripts, as well as low G-CSF levels. 61 However, the diagnosis remains difficult and an abnormal karyotype is helpful in distinguishing it from a more common leukaemoid reaction, because of an underlying infection or malignancy. 62 Furthermore, the diagnosis can only be made with confidence once BCR-ABL disease has been excluded, particularly as an isolated neutrophilia has been associated with the p230 BCR-ABL transcript. 62 These cases, termed neutrophilic-chronic myeloid leukaemia (CML-N) may have a more indolent clinical course when compared with patients with the standard p210 transcript, a fact thought to be related to low p230 mRNA and protein expression levels. 63 A review of the CNL literature suggested that cytogenetic abnormalities occur in approximately a third of cases, with del(20q) being the most frequent finding. 62, 64 Other reported abnormalities include trisomy 8, 65 trisomy 21 66 and t(1;20), 67 although none are specific for CNL. A normal karyotype, however, characterizes the majority of cases, a finding that suggests that the initial genetic event is submicroscopic and not visible by conventional cytogenetic analysis. Indeed, it has been suggested that the chromosomal changes identified to date may reflect cytogenetic evolution and be secondary events in the pathogenesis of the disease. 64 Finally, cytogenetics studies have indicated that the origin of the neoplastic clone in CNL may be at the committed stem cell level, 68 although this finding has not been supported by X-linked clonality studies. 69 
Specific chromosomal abnormalities
Chromosome 1
Structural changes leading to partial, or total trisomy 1q are characteristic findings in Philadelphia-negative MPNs. They account for approximately 10% of abnormal karyotypes in PV and PMF, 27, 28, 70 a figure that increases to between 70-90% in patients with post-PV MF. 71 Trisomy 1q is likely to be a secondary event in post-PV MF, as it frequently coexists with other abnormalities known to be present at diagnosis, such as del(20q). 71 The rearrangements of 1q follow a definite nonrandom pattern and may be caused by many mechanisms, including unbalanced translocations with many variable chromosome partners that results in trisomy 1q, as well as partial duplications of 1q that involve a critical region between 1q21 and 1q32. [71] [72] [73] The underlying mechanisms for these changes are unclear, although the methylation status of the centromeric DNA of chromosome 1 could be relevant in the MPNs. It is known, for example, that hypo-, or demethylation of heterochromatin of chromosome 1 is associated with DNA decondensation, making it more prone to breakage and subsequent rearrangements. 74 Another study reported trisomy 1q in a case of dic(1;15) (p11;p11), in which the heterochromatic sequences were thought to play a role in the juxtaposition of the long arm of chromosome 1 and the peri-centromeric region of the acrocentric chromosome. 75 Furthermore, a study of a series of patients with MPNs and 1;9 translocations concluded that the heterochromatin juxta-positioning of the satellite II family of 1q and satellite III of 9q, because of their structural homologies, may favour heterochromatin recombination. 76 The variable breakpoints and lack of a preferential translocation site indicates that an increase in gene(s) copy number could also be important. In support of this concept, Zanke et al. 77 have reported an associated amplification and overexpression of a haematopoietic protein tyrosine phosphatase in such cases. However, a number of alternative hypotheses have been proposed, including the silencing of genes closely located to heterochromatin that have been moved as a result of the chromosome abnormality and/or the interference of proteins that normally associate with heterochromatin. 78 
Chromosome 8
Trisomy 8 is commonly associated with myeloid malignancies, especially PV and PMF, [27] [28] [29] and is principally found as an isolated finding, although occasionally in association with trisomy 9. 71 The result of conventional cytogenetic analysis, however, can be uncertain; including situations where only a single abnormal metaphase is identified as, according to the ISCN definition (ISCN), clonality requires the observation of two or more abnormal cells to be present. 79 Interestingly, Jenkins et al. 80 have reported that the incorporation of FISH studies, with centromeric probes for chromosome 8, can be of value in such cases as its sensitivity appears greater than standard cytogenetics. The genetic consequences of chromosome 8 duplication remain unclear, although a recent study has suggested a role for microRNAs. 81 The latter are small, noncoding, RNAs of between 19-25 nucleotides that act as regulators of gene expression by inducing translational inhibition and cleavage of target mRNAs. Recently, their expression has been linked to haematopoiesis and cancer. 82 Interestingly, in cases of trisomy 8, miR-124a and miR-30d located on 8p21 and 8q23 respectively, are overexpressed suggesting that a gene dosage effect may be contributing to this finding. It may be relevant that miR-124a targets the myeloid transcription factor CEBPa, 83 although pathogenetic studies in CMPDs are awaited.
Chromosome 9
The incorporation of interphase fluorescence in situ hybridization (I-FISH) and comparative genomic hybridization (CGH) has provided evidence for the pathogenetic involvement of the short arm of chromosome 9 in PV. Such techniques can be applied to non-dividing cells and, as a result, have a greater sensitivity than conventional cytogenetics for the detection of specific abnormalities. Amiel et al., 84 for example, provided preliminary data to suggest that trisomy 9, as well as trisomy 8, were more common in PV than had previously been appreciated. Subsequent studies have reported that partial trisomy of the short arm of chromosome 9 and an additional i(9)(p10) to be new and recurrent primary chromosomal abnormalities in PV and led to the conclusion that amplification of a gene, or genes, on 9p may play a crucial role in the disease's pathogenesis. 85, 86 Such an interpretation has been supported by reports from a number of groups. For example, gain of 9p, either as a trisomy or tetrasomy, resulting from an unbalanced translocation, or as a sole abnormality, has been reported in PV patients, with the critical region appearing to lie between p13 and pter. [87] [88] [89] Bacher et al. 90 reported a gain of 9p because of an unbalanced rearrangement der(9;18), whereas Al-Assar et al., 91 in a study incorporating CGH, reported gains of 9p in 50% of PMF cases that involved 9p13 and 9p23. A similar amplified region, 9p22-p24.3 has been identified in a case of PV that transformed to acute myeloid leukaemia with resultant amplification of MLLT3, JMJD2C, JAK2 and SMARCA2 genes. 92 However, although amplification of such genes has been implicated in solid tumours, their role in MPDs remains unclear. Nevertheless, these and other studies suggested that gene(s) on 9p, rather than 9q, are crucial to the pathogenesis of PV. 93 In an attempt to clarify further the genomic regions that cause the PV phenotype, Kralovics et al. 94 carried out a genome-wide microsatellite screen for LOH. Three genomic regions were identified on chromosomes 9p, 10q and 11q, with LOH of the 9p being found in a third of cases, making it the most frequent chromosomal lesion described at the time. The authors concluded that mitotic recombination accounted for the 9pLOH, as there were no cytogenetic losses in affected subjects and that the involved region extended to the telomere. Interestingly, this finding of uniparental disomy, which involves the entire short arm of chromosome 9, is not detectable by cytogenetic analysis, FISH or CGH. Subsequently, markers from the 9pLOH region were reported not to cosegregate with the phenotype in familial PV, suggesting that a somatic event caused the 9pLOH. 95 Ultimately, fine mapping of the region identified JAK2, located at 9p24.1, as a likely candidate gene and led to the group detecting the JAK2 V617F-activating mutation in the majority of PV patients.
12 Three other teams, using different methodological approaches, reported identical findings at around the same time.
10,11,13
Chromosome 13
Deletion of 13q is a common abnormality in the MPNs, especially PMF, although to a lesser extent in post-polycythemia myelofibrosis (Post-PV MF). 27, 28, 71 It has been commonly interpreted as interstitial, with proximal and distal breakpoints in 13q12 and 13q14-q22, respectively. 96 As the retinoblastoma susceptibility gene (RB-1) is located in this region, it has been postulated that its inactivation may be pathogenetically important. 97 However, Pastore et al. 98 found no structural changes in the Rb-1 gene, even in those cases that exhibited loss of heterozygosity at the locus. Standard cytogenetic analysis of these cases failed to detect a 13q abnormality, suggesting the presence of cryptic deletions (Gaidano, personal Communication). However, another study, using FISH to detect Rb-1 deletions, reported hemizygous gene deletion only in those cases with 13qÀ on standard cytogenetic analysis. 99 Similarly, Tanaka et al. 100 reported Rb-1 allelic loss, in addition to the microsatellite loci D13S319 and D13S25, in cases of myeloid malignancy with deletion/translocation at 13q14. Two further studies have confirmed these findings and emphasized that 13q deletions are associated with considerable genetic loss.
101,102
The situation appears similar for 20q deletions and supports the view that cryptic deletions appear rare. 103 Translocations involving 13q14 have been reported, 57, 99, 102 and it was hoped that detailed examination of these rare cases would help in the identification of pathogenetically relevant genes. Unfortunately, several studies have shown that large submicroscopic deletions, involving the same commonly deleted region as defined for 13q deletions, are characteristic of these apparently balanced translocations. 101, 102, 104, 105 This suggests that translocations involving 13q14 may have the same underlying pathogenetic mechanism and that study of such cases is unlikely to help in the search for the relevant genes. Finally, it is possible that more than one gene is involved on chromosome 13, as a study of a case of PMF and t(4;13) (q25;q12) suggested the involvement of a novel gene on 13q12. 106 Trisomy 13, although a well described abnormality in acute leukaemia, 107 has occasionally been reported in Philadelphianegative MPNs. A few cases have been diagnosed as PMF, 108 although the majority appear to have a 'CML-like' disorder. 109 
Chromosome 20
Deletion of chromosome 20q, which was originally described in 1966 as an F-group chromosomal deletion in PV, 110 occurs in a range of myeloproliferative disorders. 111 It is a common finding, for example, not only in PV, [53] [54] [55] but also in PMF [26] [27] [28] 112 and may occur in ET, 114, 115 chronic neutrophilic leukaemia, 62 myelodysplastic syndromes 113, 114 and acute myeloid leukaemia, 115 although rarely in lymphoproliferative malignancies. 116, 117 It is mostly found as an isolated event, although in approximately a quarter of cases it can occur with additional cytogenetic abnormalities including deletion 5q, monosomy 7, trisomy 8, deletions and translocations of 13q and trisomy 21. The 20q breakpoints appear to be heterogeneous, as evidenced by the variable size of the deletion by standard cytogenetics, 118 FISH analysis 119 and by the early molecular studies, which demonstrated the variable retention of the SRC gene.
120,121 Such a conclusion was confirmed by Nacheva et al., 113 who showed variable size deletion using highresolution banding, with a commonly deleted region spanning 20q11.2-q13.1. Roulston et al. 119 used multiple probes to study the deletion in 19 cases of myeloid disease and defined a commonly deleted region flanked by RPN2 (20q11.2) proximally and D20S17 (MLRG) distally. Wang et al. 122 narrowed the segment to an area of 8 Mb flanked by a proximal boundary between markers D20S206 and D20S107 and a distal boundary between D20S119 and D20S424, whereas Bench et al. 123 refined it further, to a 2.7-Mb region spanning from D20S108 to D20S481. Furthermore, the latter group identified six genes and 10 unique expressed sequence tags, of which five were expressed in both normal bone marrow and purified CD34 þ cells. These six genes, therefore, represent positional and expression candidates for the 20q target and include the L3MBTL gene (also known as h-l(3)mbt). Interestingly, MacGrogan et al., 124 after identifying six candidate genes by physical mapping of translocation breakpoints in a variety of myeloid leukaemia cell lines, also concluded that L3MBTL might be pathogenetically important.
L3MBTL was identified as a candidate suppressor gene by virtue of its homology to the Drosophila tumour suppressor gene lethal (3) malignant brain tumour. 125 It appears that correct levels of L3MBT are important for normal progression through mitosis, as both overexpression and loss of activity can affect cell division. Furthermore, Boccuni et al. 126 have suggested that the protein functions as an HDAC independent transcription repressor, which can be recruited by direct binding to TEL (ETV6). Despite these findings, the role of L3MBT in the pathogenesis of del(20q) myeloid disorders is unclear, as no mutations have been identified, 127 although the demonstration that L3MBTL is monoallelically expressed raises the possibility that deletion of the paternally derived chromosome 20 might be relevant. 128 Studies of patients with 20q deletions have provided some valuable insights into the biology of the MPNs. They indicate, for example, that in at least some cases the lymphoid lineage may be involved. In a patient with ET and 20qÀ, the deletion was detected in myeloid, erythroid, CD34 þ progenitor cells, as well as CD10 þ lymphoid cells. 129 Furthermore, a lymphoblastoid cell line derived from a patient with a Philadelphiapositive ALL contained the 20q deletion, as did the CFU-GM, CFU-GEMM and BFU-E. 130, 131 These two reports imply that CMPDs may arise in an early progenitor cell with both myeloid and lymphoid potential. This conclusion is also supported by studies in PMF, in which the involvement of B and T cells has been documented. 132, 133 Intriguingly, a case of myelodysplasia has been published in which the 20q deletion was present in the multilineage progenitor cells but not the peripheral blood lymphocytes. 134 This finding suggests that either the clonal B cells have a reduced lifespan, or that the involved progenitor cells have an impaired ability to give rise to mature B lymphocytes. A further insight from cytogenetic studies is the paradoxical observation that 20q deletions, which characterize myeloproliferative disorders, may also severely impair granulocyte release into the peripheral blood. Asimakopoulos et al., 135 for example, have shown that some patients with 20q deletions in all bone marrow metaphases have cytogenetically normal peripheral blood granulocytes and that this appears to result from the 20qÀ cells being preferentially retained and/or destroyed in the bone marrow.
Cytogenetics and JAK2 mutations
A number of groups have correlated the pattern of cytogenetic abnormality with the presence of a JAK2 mutation. Campbell et al., 137 for example, reported that MPN patients with either trisomy 9/ þ 9p or 20qÀ are invariably JAK2V617F-positive 136 whereas a recent FISH study has confirmed these findings in a cohort of PV patients. Interestingly, the majority of cases in the latter study also possessed amplification of JAK2, in addition to the V617F mutation, suggesting that JAK2 copy number may play a pathogenetic role. These results imply a role for cooperating mutations in the pathogenesis of JAK2 V617F-positive MPNs and support the hypothesis that dosage of JAK2 contributes to the disease phenotype in which an increased constitutive activation of JAK2 provides a proliferative advantage. 138 Cytogenetics, when combined with JAK2 mutational screening, has also provided evidence of a common clonal origin for at least some cases of MPNs and AML and for the fact that JAK2 mutations may not be the initiating event. Theocharides et al., 139 for example, reported a single case with JAK2-V617F-positive PMF in which JAK2-V617F was absent from the blasts at the time of transformation. However, del(11q) was found in all metaphases by cytogenetic analysis and by I-FISH, suggesting that the JAK2-V617F-negative blasts and the JAK2-V617F-positive bone marrow cells carried the same deletion. Intriguingly, the same region on chromosome 11 had been reported in a genome-wide screening for LOH. 94 This cytogenetic finding implies the presence of subclones from a common clonal ancestor in the development of PMF and AML and suggests that an initial clonal event may precede the acquisition of JAK2-V617F in the pathogenesis of MPNs. 139, 140 Using deletions of chromosome 20 as an autosomal, X-chromosome-independent clonality marker, Kralovics et al. 141 found a similar discrepancy between percentage of cells carrying JAK2 V617F and del(20q). Similar conclusions have also been suggested by Campbell et al.
136
Cytogenetics and prognosis
In general, the prognostic value of cytogenetics in the MPNs, with the exception of PMF, has not been established. 58 Rare karyotypic abnormalities, however, may be associated with a greater risk of undergoing myelofibrotic or leukaemic transformation. For example, Larsen et al., 142 on reviewing the literature, concluded that JAK2 V617F-positive cases with a der(9;18)(p10;q10) may have a high intrinsic propensity for such transformations. The molecular basis for this observation remains unclear, although the possibility of JAK2 gene amplification requires further study. Other abnormalities, unrelated to therapy, that have a poor outcome include the de novo appearance of der(1;7(q10;p10)) in ET. 143 In total eight cases have been reported, of which six underwent leukaemic and one a myelofibrotic transformation. [144] [145] [146] [147] [148] Similar findings have been reported for der(1)t(1;9) in PV and PMF 149 and for t(6;10)(q27;q11) in PMF. 150 Structural abnormalities of the long arm of chromosome 12, non-random findings in myelofibrosis, confers a poor prognosis because of early blast transformation, 151 whereas Strasser-Weipel et al. 152 reported the poor prognosis of chromosome 7 deletions (À7/7qÀ), although somewhat surprisingly this was not related to leukaemic transformation. Patten et al. 153 have reported an association between a lack of committed erythroid progenitor cells in PMF and chromosome 11 abnormalities and suggested the existence of genes on this chromosome which has an important function during erythropoiesis.
Several early studies suggested that an abnormal karyotype per se carries a poor prognosis for PMF patients. The first to highlight this association were Besa et al., 154 albeit indirectly, after noting that response to androgen therapy was dependent on karyotype. Confirmation was provided by Demory et al. 26 in a study of 47 cases, in which the adverse prognosis of an abnormal karyotype retained its significance on both univariate and multivariate analysis. The same group subsequently confirmed these findings in a larger cohort of PMF patients 155 and demonstrated that an abnormal karyotype carried a greater risk of acute transformation. Similar prognostic results were reported by Reilly et al. 27 and led to the incorporation of karyotypic findings, together with age and haemoglobin levels, into a prognostic scoring model. Patients below the age of 69 years who did not have either anaemia (haemoglobin o10 g/dl) or an abnormal karyotype had a median survival of 180 months, compared with 22 months for the age-matched cohort, with both anaemia and abnormal cytogenetics.
Transplantation outcome may also be dependent on karyotype. Deeg et al., 156 for example, in a study of 56 patients concluded that, other than Lille score, 155 an abnormal karyotype had the strongest negative effect on post-transplant mortality. Interestingly, the frequency of chromosomal abnormalities is significantly lower in younger patients, 157 ,158 a fact that may account for their better prognosis. Indeed, a normal karyotype is characteristic of paediatric patients and, because of their better prognosis, may indicate both a different pathogenesis and the need for a more conservative management. 159 Two recent reports from the Mayo Clinic, one retrospective 28 and the other prospective, 160 have suggested that not all cytogenetic abnormalities are associated with an adverse prognosis in PMF. For example, they reported that the commonest abnormalities, namely13qÀ and 20qÀ, may have little impact on survival, in contrast to trisomy 8 and 12qÀ which were independent prognostic determinants, together with age and anaemia, of an inferior outcome. Such a conclusion has been strengthened by similar results from a study of post-polycythemia myelofibrosis and post essential thrombocythemia myelofibrosis. 161 Indeed, the authors concluded that every effort should be made to determine the cytogenetic profile of patients with PMF or secondary MF, including the use of FISH if marrow samples are unavailable. A further rationale for routine analysis is the likely prognostic implications of identifying patients with del(5q). Tefferi et al., 162 for example, have shown significant responses of such cases to the immunomodulatory drug lenalidomide (CC-5013, Revlimid), in contrast to the limited response in PMF patients lacking such an abnormality. 163 The mechanism of lenalidomide's action remains unclear but it may relate to the induction of G0-G1 growth arrest in malignant rather than normal cells. 164 Finally, detailed molecular profiling may provide additional prognostic information. For example, a recent Italian study reported that expression levels of both CD9 and DLK1 are associated with platelet count, whereas high WT1 expression identifies PMF cases with more active disease, as evidenced by elevated CD34 þ cell count and a higher severity score. 
